Clinical Trial Supply And Logistics Market to Reap Excessive Revenues By 2028

 Clinical Trial Supply And Logistics Market Growth & Trends

The global clinical trial supply and logistics market size is expected to reach USD 5.4 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.1% from 2021 to 2028. The market growth is attributed to the increasing need to manage clinical trials and innovations and technology advancements in clinical trial supply and logistics services

However, the COVID-19 pandemic had a negative impact on the market due to restrictions imposed by countries, which led to a 95% reduction in commercial airlines. Besides, clinical trials have increased due to the rising demand for the Covid-19 vaccine. According to the WHO, more than 80 vaccines are currently being studied in clinical trials, with over 180 in the pre-clinical stage. There would be a challenge for logistics related to timelines and access to a large population.

Digitalization tools are required to overcome these challenges for future trials. For instance, a kit with a scannable label can be monitored throughout the supply chain from the kit assembly line to the patient’s home. Machine learning algorithms can take the process a step further by considering various factors across multiple supply chains, such as capacity or hours of service. Radio-frequency identification (RFID) can also aid in the management of shipments required for these clinical trials.

Request a free sample copy or view report summary: Clinical Trial Supply And Logistics Market Report

Clinical Trial Supply And Logistics Market Report Highlights

• The logistics and distribution service segment dominated the market in 2020 with a revenue share of over 20.0% owing to an increase in clinical trials as a result of Covid-19
• Based on phase, the phase III segment dominated the market with a revenue share of over 40.0% in 2020
• In terms of end-user, the pharmaceuticals segment held the largest revenue share of over 40.0% in 2020. This is due to the investment by companies and the presence of a large number of players in the market
• By therapeutic area, the cardiovascular diseases segment dominated the market with a revenue share of over 25.0% in 2020 due to an increase in the number of cardiovascular research studies and firms focused on bringing innovative drugs to the market
• Asia Pacific is anticipated to register the fastest growth rate of 7.8% throughout the forecast period. The region has access to a large and diversified patient pool, cheaper recruitment costs, and favorable policies that make Asia Pacific desirable for clinical trials

Access Press Release@ https://www.grandviewresearch.com/press-release/global-clinical-trial-supply-logistics-market

Clinical Trial Supply And Logistics Market Segmentation

Grand View Research has segmented the global clinical trial supply and logistics market based on service, phase, end-user, therapeutic area, and region:

Clinical Trial Supply And Logistics Service Outlook (Revenue, USD Million, 2016 - 2028)

• Logistics & Distribution
• Storage & Retention
• Packaging, Labeling, and Blinding
• Manufacturing
• Comparator Sourcing
• Other Services (Solutions, Ancillary Supply)

Clinical Trial Supply And Logistics Phase Outlook (Revenue, USD Million, 2016 - 2028)

• Phase I
• Phase II
• Phase III
• Phase IV

Clinical Trial Supply And Logistics End-user Outlook (Revenue, USD Million, 2016 - 2028)

• Pharmaceuticals
• Biologicals
• Medical Device

Clinical Trial Supply And Logistics Therapeutic Area Outlook (Revenue, USD Million, 2016 - 2028)

• Oncology
• Cardiovascular Diseases
• Respiratory Diseases
• CNS and Mental Disorders
• Others

Clinical Trial Supply And Logistics Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Iran
  • Israel

List of Key Players of Clinical Trial Supply And Logistics Market

• Thermo Fisher Scientific (Patheon)
• Catalent, Inc.
• Parexel
• Almac Group
• Marken
• Piramal Pharma Solutions 
• UDG Healthcare
• DHL
• FedEx
• Movianto
• Packaging Coordinators Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Demand for Europe Pharmaceutical Market Increasing in Most Part of World 2028

 Europe Pharmaceutical Market Growth & Trends

The Europe pharmaceutical market size is expected to reach USD 432.12 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 5.4% from 2021 to 2028. The market is driven by an increasing prevalence of diseases, a growing elderly population, and the approval and launch of novel products in the European region.

Overall, the pharmaceutical market in Europe is dominated by branded drugs; however, the generic drugs segment is anticipated to grow at the fastest rate over the forecast period. Loss of patent protection of key pharmaceutical products and increasing government initiatives to adopt generic drugs for the treatment are some of the key factors likely to boost generics demand in the coming years.

The capitalization opportunity is high for generic manufacturers in the European market as governments from each region are forming plans to meet the population’s demand and lower healthcare-associated expenditure of the country. The expiration of patent exclusivities and the building need for cost-effective treatments are fueling the penetration of biosimilars and generics.

Novel molecule entry in this market typically takes 12-13 years and an investment of over USD 2.5 billion. In 2019, the total R&D expenditure on pharmaceutical R&D was USD 44,881.92 million. Increased competition from growing economies, such as China and Brazil, has accelerated the European economic investment in research to maintain its dominance in the market.

Improvements in healthcare infrastructure are promoting the adoption of novel pharmaceuticals. Furthermore, an increase in drug launches in Europe is projected to propel the market growth. For instance, in 2020, 62 drugs were approved in Europe and 97 medicines received marketing approval in European countries. The highest number of drug approvals were observed in the oncology segment.

Key pharmaceutical companies offer strong branded drugs in multiple therapeutic segments. Increasing R&D efforts, the growing adoption of novel therapies, and strategic collaborations are likely to boost the penetration of branded drugs. Strong pipeline products in different therapeutic areas are likely to fuel the growth of branded drugs in Europe.

Request a free sample copy or view report summary: Europe Pharmaceutical Market Report

Europe Pharmaceutical Market Report Highlights

• By therapeutic category, the oncology segment is expected to grow at the fastest rate owing to the increasing prevalence of cancer along with the entry of novel molecules into the market
• Based on product, generic drugs are expected to emerge as the fastest-growing segment over the forecast period owing to the increased preference of the consumers for generic drugs due to their cost-effectiveness
• In terms of type, the prescription segment held the largest share in 2020 owing to the presence of the majority of pharmaceuticals in the prescription category
• Western Europe held the largest share in 2020 owing to the presence of countries with developed healthcare systems
• The preference of companies for contract manufacturing is rising in Europe due to the specialized nature of pharmaceutical products and reasonable production costs

Access Press Release@ https://www.grandviewresearch.com/press-release/europe-pharmaceutical-market-analysis

Europe Pharmaceutical Market Segmentation

Grand View Research has segmented the Europe pharmaceutical market based on product, type, therapeutic category, and region:

Europe Pharmaceutical Product Outlook (Revenue, USD Billion, 2017 - 2028)

• Branded
• Generic

Europe Pharmaceutical Type Outlook (Revenue, USD Billion, 2017 - 2028)

• OTC
• Prescription

Europe Pharmaceutical Therapeutic Category Outlook (Revenue, USD Billion, 2017 - 2028)

• Oncology
• Cardiovascular Diseases
• Anti-infectives
• Central Nervous System Disorders
• Metabolic Disorders
• Gastrointestinal Disorders
• Respiratory Diseases
• Other Disorders

Europe Pharmaceutical Regional Outlook (Revenue, USD Billion, 2017 - 2028)

• Western Europe
  • UK.
  • France
  • Germany
  • Italy
  • Spain
• Central & Eastern Europe
  • Poland
  • Hungary
  • Switzerland
• Nordic Regions
  • Denmark
  • Finland
  • Norway
• Rest of Europe

List of Key Players of Europe Pharmaceutical Market

• Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• Johnson & Johnson Services, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc.
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi
• Boehringer Ingelheim GmbH

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Chloroprene Rubber Market Witness Excellent Revenue Growth During 2021-2028: Grand View Research Inc

 Chloroprene Rubber Market Growth & Trends

The global chloroprene rubber market size is expected to reach USD 1.39 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 4.6% from 2021 to 2028. Increasing adoption of chloroprene rubber in the automotive, electrical & electronics, construction, and textile industries is projected to fuel the market growth during the forecast period. It is widely used in tire sidewalls, automotive trims, gaskets, and related products owing to the rising demand for Electric Vehicles (EVs).

The growing requirement for electrical power is expected to drive the demand for electric cables for power transmission. This is expected to drive the product demand in cable jackets. The rising private & public investments in the construction sector focusing on the development of infrastructure projects across the globe remain critical to the product demand in construction applications. The product has a wide scope of application in the manufacture of rubber pads products due to the demand arising from the construction industry.

Major key players in the market are investing in expanding and developing chloroprene for end-use industries. For instance, in April 2021, ARLANXEO established ARLANXEO India Private Limited in India to strengthen its position in the Indian market to meet the needs of quickly expanding industries, such as pharmaceuticals, tires, automotive, and end-user products.

The demand for industrial products and chemicals in countries such as China, Japan, India, South Korea, and Thailand is expected to impact the consumption of chloroprene rubber used in these products. Many elastomer manufacturers are carrying out research and development activities to develop a vulcanization process for manufacturing chloroprene rubber to replace the existing smoked rubber suppression technique. One of the main advantages offered by the vulcanization process is the improvement in absorbent properties. This has helped position chloroprene rubber as a suitable material for manufacturing protective lining in chemical plants.

Request a free sample copy or view report summary: Chloroprene Rubber Market Report

Chloroprene Rubber Market Report Highlights

• In terms of revenue, the automotive application segment accounted for the largest revenue share of more than 35% in 2020. It is expected to grow further at a steady CAGR over the forecast period
• Asia Pacific was the largest regional market in 2020 and accounted for more than 50.0% of the global revenue share
• China was the largest producer of vehicles in the Asia Pacific. Rising consumer disposable income levels in the country coupled with the high demand for EVs and luxury cars will; boost the product demand in automotive applications in China
• Various strategic initiatives were recorded over the past few years to boost the growth of the market
• For instance, in August 2020, Tosoh Corporation collaborated with Bando Chemicals to develop cost-reducing technology for manufacturing CNF-reinforced chloroprene rubber to be used in transmission belts in the automobile sector

Access Press Release@ https://www.grandviewresearch.com/press-release/global-chloroprene-rubber-market

Chloroprene Rubber Market Segmentation

Grand View Research has segmented the global chloroprene rubber market on the basis of application and region:

Chloroprene Rubber Application Outlook (Volume, Kilotons; Revenue, USD Million, 2017 - 2028)

• Automotive
• Electrical & Electronics
• Construction
• Textile
• Others

Chloroprene Rubber Regional Outlook (Volume, Kilotons; Revenue, USD Million, 2017 - 2028)

• North America
  • US.
• Europe
  • Germany
• Asia Pacific
  • China
  • India
  • Japan
• Central & South America
• Middle East & Africa

List of Key Players of the Chloroprene Rubber Market

• Tosoh Corp.
• Denka Company Ltd.
• ARLANXEO
• SEDO Chemicals Neoprene GmbH
• QingDao Nova Rubber

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Neurology Clinical Trials Market Set to Witness an Uptick during 2021 to 2028: Grand View Research Inc.

 Neurology Clinical Trials Market Growth & Trends

The global neurology clinical trials market size is expected to reach USD 7.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.5% from 2021 to 2028. This is largely attributed to big pharma companies conducting innovative trials in neurology, increased government funding from the National Institute of Neurological Disorders and Stroke (NINDS), and stringent regulatory requirements pertaining to clinical trials. 

Neuroscience continues to receive a healthy level of early investment. It received USD 1.5 billion in venture capital funding in 2018, second only to cancer, indicating that investors expect a large pharma acquisition to pay off in the near future. As the industry strives to move past the many late-stage clinical failures of recent years, early diagnosis of diseases is attracting investment and driving deal-making in the complex neuroscience sector, particularly for pain and Alzheimer's disease.

In terms of deal volume, no other therapy area comes close to matching oncology, but neuroscience is among the nearest contenders. Despite a drop in total expected value in 2017, the number of neuroscience-related licensing deals has gradually climbed over the last decade. The vast majority of neuroscience agreements ~90%have a primary neurological focus, which corresponds to the level of R&D activity in the two disciplines.

Many experimental therapeutics require dosage by on-site administration and carefully scheduled outcome measure evaluations hence, the COVID-19 pandemic has significantly harmed the implementation of the precise procedures required to establish proof of safety and efficacy. The COVID-19 has resulted in the shutdown of the network of centers conducting stroke clinical trials. This was followed by a phased research restart plan that took local circumstances and regulatory oversight into account. This approach was successful in a reengaging research effort to some extent in all but one of the ongoing investigations within 55 days.

Request a free sample copy or view report summary: Neurology Clinical Trials Market Report

Neurology Clinical Trials Market Report Highlights

• The phase II segment dominated the market and accounted for a maximum revenue share of 36.7% in 2020. Between 1999 and 2020, 8,205 CNS trials were conducted, with 609 trials being conducted in 2020
• The interventional segment held the largest market revenue share of 81.1% in 2020
• The Huntington's disease segment is anticipated to register the fastest CAGR of 6.0% over the forecast period. This is largely due to the high prevalence of the disease around the world
• North America dominated the market and accounted for a revenue share of 45.8% in 2020. The rising prevalence of neurological disorders and the presence of a large number of players in clinical trials drive the market in the region

Access Press Release@ https://www.grandviewresearch.com/press-release/global-neurology-clinical-trials-market

Neurology Clinical Trials Market Segmentation

Grand View Research has segmented the global neurology clinical trials market based on phase, study design, indication, and region:

Neurology Clinical Trials Phase Outlook (Revenue, USD Million, 2016 - 2028)

• Phase I
• Phase II
• Phase III
• Phase IV

Neurology Clinical Trials Study Design Outlook (Revenue, USD Million, 2016 - 2028)

• Interventional
• Observational
• Expanded Access

Neurology Clinical Trials Indication Outlook (Revenue, USD Million, 2016 - 2028)

• Epilepsy
• Parkinson's Disease (PD)
• Huntington's Disease
• Stroke
• Traumatic Brain Injury (TBI)
• Amyotrophic Lateral Sclerosis (ALS)
• Muscle regeneration
• Others

Neurology Clinical Trials Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

List of Key Players of Neurology Clinical Trials Market

• IQVIA
• Novartis
• Covance
• Medpace
• Charles River Laboratories
• Syneous Health
• Icon Plc
• GlaxoSmithKline
• Aurora healthcare
• Biogen

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Current And Future Market Conditions 2021-2028: Grand View Research Inc.

 In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Growth & Trends

The global in-vitro toxicology assays market size for cannabis and nicotine testing is expected to reach USD 2.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.2% from 2021 to 2028. Growing adoption of high throughput techniques in cannabis testing, legalization of medical cannabis, and growing awareness regarding the potential hazards of nicotine consumption have majorly driven the market throughout the forecast period.

The legalization of medical cannabis is underway globally, including in countries such as Germany, Australia, and Israel. The market is gaining momentum in the Asia Pacific region, with Thailand having fully legalized medicinal cannabis. Thus, increasing legalization of medical cannabis is expected to drive the market growth to a major extend. In addition, technological advancements in cellular assays have boosted the market growth.

COVID-19 has become a catalyst for changing the traditional use of cannabis. Owing to the pandemic, the leading scientific community and market competitors are now focusing on deciphering the potential of cannabis to prevent SARS-CoV-2 infection. Companies have reported the increase in the sale of cannabis as some states/countries have declared cannabis as an essential medicine during the pandemic.

Request a free sample copy or view report summary: In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Report

In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Report Highlights

• Nicotine testing accounted for the largest revenue in 2020 and is expected to continue the trend in the forecast period owing to increasing safety concerns associated with nicotine products
• Cannabis testing is expected to witness gradual growth through 2021-2028 owing to the rising acceptance of cannabis for medical use
• 3D cell culture technology is expected to grow at substantial CAGR owing to the increasing popularity of drug development and toxicity testing
• Cytotoxicity testing designing accounted for the highest market revenue in 2020 owing to advancements in different tools for evaluating the cytotoxic effects of nicotine-containing products
• North America has emerged as the highest revenue-generating region in 2020, owing to the prevalence of cancer, presence of key players, and developed healthcare infrastructure
• Asia Pacific is anticipated to witness the fastest CAGR throughout the forecast period. It is anticipated that China and India are contributing majorly to the regional market’s growth
• Key players are undertaking various strategic initiatives such as mergers and acquisitions to maintain their presence in the market
• In August 2020, Eurofins Scientific purchased approximately 136 smaller labs within 3 years from 2014 to 2019, accounting for a total expenditure of USD 3.4 billion in these acquisitions

Access Press Release@ https://www.grandviewresearch.com/press-release/global-in-vitro-toxicology-assays-cannabis-nicotine-testing-market

In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Segmentation

Grand View Research has segmented the global in-vitro toxicology assays market for cannabis and nicotine testing on the basis of test type, technology, application, method, and region:

In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Type Outlook (Revenue, USD Million, 2017 - 2028) 

• Cannabis Testing
• Nicotine Testing

In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Technology Outlook (Revenue, USD Million, 2017 - 2028)

• 3D Cell Culture Technology
• Mass Spectrometry
• Flow Cytometry
• Others

In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Application Outlook (Revenue, USD Million, 2017 - 2028)

• Genetic Toxicity Testing
• Carcinogenicity Testing
• Cytotoxicity Testing
• Mutagenicity Testing
• Others

In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Method Outlook (Revenue, USD Million, 2017 - 2028)

• Cellular Assay
  • Live Cells
    • High Throughput / High Content Screening
    • Molecular Imaging
    • Others
  • Fixed Cells
• Others

In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Spain
  • Italy
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Singapore
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia

List of Key Players of In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing

• Stemina Biomarker Discovery, Inc.
• Broughton Nicotine Services
• Labstat International, Inc.
• IONTOX
• TOXIKON
• Integrated Laboratory Systems
• Enthalpy Analytical
• PBR Laboratories, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Extracorporeal CO2 Removal Devices Market Trends, Demand, Production, Analysis and Forecast to 2028: Grand View Research Inc.

 Extracorporeal CO2 Removal Devices Market Growth & Trends

The global extracorporeal CO2 removal devices market size is estimated to reach USD 118.64 million by 2028, registering a CAGR of 5.27% over the forecast period, according to a new report by Grand View Research, Inc. Technological improvements have changed extracorporeal techniques for CO2 removal in a promising manner to avoid respiratory failure, worsening respiratory acidosis, and to possibly shorten or prevent the duration of invasive mechanical ventilation in patients with exacerbation of asthma and Chronic Obstructive Pulmonary Disease (COPD).

Extracorporeal CO2 removal devices are considered to be an efficient therapy for patients suffering from hypercapnia respiratory failure and may allow clinicians as well as healthcare professionals to improve lung-protective ventilation. These devices can remove adequate CO2 to allow a 50% reduction in alveolar minute ventilation resulting in a substantial reduction in PaCO2. Hence, various advantages associated with these devices are expected to augment the overall market growth.

Extracorporeal CO2 removal devices are effective, safe, and feasible. The usage of these tools in ventilation support has been suggested in clinical situations where they may be useful, including exacerbation of COPD and Acute Respiratory Distress Syndrome (ARDS). The increasing prevalence of COPD across the globe is predicted to accelerate market growth. According to the British Lung Association, around 1.2 million people are diagnosed with COPD in the U.K.

Several manufacturers in the market are focusing on developing technologically advanced and innovative devices to strengthen their industry position. For instance, in November 2015, Alung Technologies received an Expedited Access Pathway (EAP) from the FDA for its Hemolung Respiratory Assist System (RAS). In February 2016, Alung Technologies received USD 12 million financing from existing as well as new investors. This financing helped in the commercialization of Hemolung RAS.

Request a free sample copy or view report summary: Extracorporeal CO2 Removal Devices Market Report

Extracorporeal CO2 Removal Devices Market Report Highlights

• Extracorporeal CO2 machines held the largest revenue share of the global market in 2020 owing to the availability of a wide range of devices
• The COPD application segment accounted for a significant revenue share of the global market in 2020
• The venovenous access segment is expected to account for the largest share by 2028 due to advantages, such as decreased invasiveness, and potential for the early mobilization of patients
• The hospitals end-use segment is estimated to have the fastest CAGR over the forecast period due to the rising number of hospitals in developing economies and increasing competition in healthcare service providers
• North America held the largest market share in 2020 and is anticipated to maintain its dominance over the forecast period
• This is attributable to the growing prevalence of COPD & ARDS and the increasing adoption of advanced devices

Access Press Release@ https://www.grandviewresearch.com/press-release/global-extracorporeal-co2-removal-devices-market

Extracorporeal CO2 Removal Devices Market Segmentation

Grand View Research has segmented the global extracorporeal CO2 removal devices market on the basis of product, application, access, end use, and region:

Extracorporeal CO2 Removal Devices Product Outlook (Revenue, USD Million, 2016 - 2028)

• Extracorporeal CO2 Machines
• Disposables
• Others

Extracorporeal CO2 Removal Devices Application Outlook (Revenue, USD Million, 2016 - 2028)

• ARDS
• COPD
• Bridge to Lung Transplant
• Others

Extracorporeal CO2 Removal Devices Access Outlook (Revenue, USD Million, 2016 - 2028)

• Venovenous
• Arteriovenous

Extracorporeal CO2 Removal Devices End-use Outlook (Revenue, USD Million, 2016 - 2028)

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Clinics
• Others

Extracorporeal CO2 Removal Devices Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

List of Key Players of Extracorporeal CO2 Removal Devices Market

• Medtronic
• Getinge AB
• Xenios AG
• Alung Technologies
• ESTOR SpA
• Medica SpA
• Aferectica Srl

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Softgel Capsules Market Poised to Expand at a Robust Pace of USD 9.1 Billion Over 2028: Grand View Research Inc.

 Softgel Capsules Market Growth & Trends

The global softgel capsules market size is estimated to reach USD 9.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.0% from 2021 to 2028. Softgel capsules are proven to be the choice of formulation for poorly soluble drugs and enhance absorption time of most drug molecules. Its advantages over tablets and other oral formulations have led to the increased adoption of softgel capsules across the globe. Ease of swallowing, taste masking, improved bioavailability, non-reactive, aesthetically appealing, and longer shelf life are the factors influencing its wide acceptance.

Leading players like Catalent, Eurocaps, and many others, are developing vegan capsules to broaden their vegan consumer base as softgel capsule segment registers nearly 40.0% of their overall revenue. Large Pharma companies like Pfizer, Novartis, Bayer, Procter and Gamble, collaborate with leading Contract Manufacturing Organizations (CMOs) to provide cost-effective products in the highly competitive market. Research to develop oral vaccines to treat respiratory infection caused by the SaRS-CoV-2 virus has fueled the R&D of softgel manufacturers. Additionally, the shift towards a healthier lifestyle and immunity-boosting vitamins, have also surged the softgel market post-outbreak of the COVID-19 pandemic.

Request a free sample copy or view report summary: Softgel Capsules Market Report

Softgel Capsules Market Report Highlights

• The gelatin segment accounted for the largest revenue share in 2020 due to its advantages over any other excipient in the excipient industry
• The vitamins and dietary supplementssegment held the largest share in 2020 in the application outlook
• Nutraceuticalheld the largest revenue-generating segment in manufacturer market, owing to the Increasing awareness of health supplements among developing nations and growing number of production houses, and surge in sales due to Covid-19 pandemic
• North America held the largest share in the market due to the Improved production technology, presence of major players within the region and increased expenditure on R&D to widen their product portfolio

Access Press Release@ https://www.grandviewresearch.com/press-release/global-softgel-capsules-market

Softgel Capsules Market Segmentation

Grand View Research has segmented the global softgel capsules market on the basis of type, application, manufacturer, and region:

Softgel Capsules Type Outlook (Revenue, USD Million, 2016 - 2028)

• Gelatin-based/Animal-based
• Non-animal-based

Softgel Capsules Application Outlook (Revenue, USD Million, 2016 - 2028)

• Antacid and anti-flatulent preparations
• Anti-anemic preparations
• Anti-inflammatory drugs
• Antibiotic and antibacterial drugs
• Cough and cold preparations
• Health supplement
• Vitamin and dietary supplement
• Pregnancy

Softgel Capsules Manufacturers Outlook (Revenue, USD Million, 2016 - 2028)

• Pharmaceutical Companies
• Nutraceutical Companies
• Cosmeceutical Companies
• Contract Manufacturing Organization

Softgel Capsules Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
  • Norway
  • Sweden
  • Russia
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Turkey
  • UAE

List of Key Players of Softgel Capsules Market

• Fuji Capsules Co Ltd.
• Sirio Pharma
• Captek
• Patheon
• Catalent
• Eurocaps
• Aenova
• Capsugel
• Procaps Laboratories
• Soft gel Technologies Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Veterinary Dermatology Drugs Market Expectations Acme Prominent Development in Developed Regions, Details Gvr Study

 Veterinary Dermatology Drugs Market Growth & Trends

The global veterinary dermatology drugs market size is anticipated to reach USD 14.6 billion by 2028, according to a new report by Grand View Research. The market is expected to expand at a CAGR of 9.3% from 2021 to 2028. Increasing incidences of dermatology diseases such as fleas and ticks and allergic dermatitis are expected to boost the market growth. Furthermore, a growing number of clinical trials related to veterinary dermatology drugs is also anticipated to fuel market growth.

Due to the COVID-19 pandemic, some market players such as experience no negative impact. For instance, Elanco experienced a growth of 6.6% in its annual revenue. Also, Vetoquinol and Zoetis reported a growth of 8% and 6.6% in their annual revenue, respectively. On the other hand, Virbac reported a decline of 0.4% in its total revenue and a 6.9% decline in its companion animal parasiticides and dermatology segment as well as bovine parasiticides segment. This neutralized the impact of COVID-19 on the market.

Growth in the companion animal population is expected to increase the demand for veterinary healthcare products, such as dermatology drugs, and boost the overall expenditure on pets. According to the American Pet Products Association report, overall spending in the U.S. pet industry was USD 95.7 Billion in 2019 and forecast to reach approximately USD 99 Billion in 2020. Veterinary care spending increased by 560% between 1994 and 2019.

The market for veterinary dermatology drugs is fairly competitive. The most notable participants in the market are Zoetis, Virbac, and Elanco, along with other manufacturers. These players are involved in new product launches, acquisitions, and partnerships to gain a competitive edge over each other. For instance, in March 2021, Virbac obtained the rights to certain early-stage parasiticides products from Elanco, hence expanding its product portfolio. Also, in February 2021, Vetoquinol acquired the rights from Elanco for the Profender product family comprising of topical dewormer products, for the market in Canada. This expanded its geographical presence.

Request a free sample copy or view report summary: Veterinary Dermatology Drugs Market Report

Veterinary Dermatology Drugs Market Report Highlights

• The companion animal segment held the dominant share of more than 70.0% in the animal type segment as of 2020 owing to the high pet ownership rate
• The oral segment held the largest market share of the route of administration segment as of 2020, accounting for more than 37.0% of the revenue share, owing to its easy availability
• The parasitic infections segment held the largest market share of the indication segment as of 2020, owing to a high prevalence of parasitic infections
• The hospital pharmacies segment held the largest market share of 42.4% in 2020 in the distribution channel segment
• In 2020, North America held the dominant share of the market owing to the increasing pet care expenditure
• In Asia Pacific, the market is expected to show lucrative growth over the forecast period owing to the growing demand for veterinary dermatology drugs in the region

Access Press Release@ https://www.grandviewresearch.com/press-release/global-veterinary-dermatology-drugs-market

Veterinary Dermatology Drugs Market Segmentation

Grand View Research has segmented the global veterinary dermatology drugs market on the basis of the animal type, route of administration, indication, distribution channel, and region:

Veterinary Dermatology Drugs Animal Type Outlook (Revenue, USD Million, 2016 - 2028)

• Companion Animal
• Livestock Animal

Veterinary Dermatology Drugs Route Of Administration Outlook (Revenue, USD Million, 2016 - 2028)

• Oral
• Topical
• Injectable

Veterinary Dermatology Drugs Indication Outlook (Revenue, USD Million, 2016 - 2028)

• Parasitic Infections
• Allergic Infections
• Others                                    

Veterinary Dermatology Drugs Distribution Channel Outlook (Revenue, USD Million, 2016 - 2028)

• Retail
• E-Commerce
• Hospital Pharmacies

Veterinary Dermatology Drugs Regional Outlook (Revenue, USD Million, 2016 - 2028)

• North America
  • US.
  • Canada
• Europe
  • UK.
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia

List of Key Players of Veterinary Dermatology Drugs Market

• Elanco
• Vetoquinol S.A.
• Ceva
• Merck & Co., Inc.
• Zoetis
• Virbac
• Bimeda, Inc.
• Vivaldis
• Bioiberica S.A.U
• Indian Immunologicals Ltd.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Intellectual Property Management Software Market is Anticipated to Upgrade USD 431.6 Million Revenue By 2028: Grand View Research Inc.

 Intellectual Property Management Software Market Growth & Trends

The global intellectual property management software market size is anticipated to reach USD 431.6 million by 2028, expanding at a CAGR of 15.6% over the forecast period, as per the research conducted by Grand View Research, Inc. Development in the Information and Communication Technologies (ICT) sector, coupled with the growing awareness and adoption of intellectual property management software across emerging economies such as China and India, are expected to offer lucrative opportunities for the market growth.

Furthermore, increasing government initiatives toward creating a digital infrastructure and regulatory framework to monetize and protect creations are also expected to contribute to the growth of the market. For instance, China’s central government has developed a specialized intellectual property division in courts to deal with infringement and is committed to streamlining enforcement processes for trademark violations. Additionally, India is building a digital infrastructure in line with the country’s national IP policy. This initiative will safeguard and promote patents while protecting intellectual properties.

The outbreak of the COVID-19 pandemic has negatively impacted the growth of the market for intellectual property management software. The lockdown restrictions imposed by various governments across the globe have significantly impacted the use of the software. However, the market is expected to witness significant growth with the gradual leniency in restrictions and resumption of businesses.

North America contributed around 40.0% to the total market share in 2020, attributed to the increasing use of patents in the region. For instance, as per the data published by United States Patents and Trademarks Office, the number of patents used in the U.S. totaled 399,055 in 2020, compared to 370,423 in 2019. The regional market is anticipated to witness steady growth over the forecast period as well.

Some of the prominent players in the market for intellectual property management software include Anaqua Inc.; Clarivate; Innovation Asset Group, Inc.; Gemalto NV; CPA Global; and Questel. These players focus on launching new products, applications, and services to enhance their business operations. For instance, in November 2019, CPA Global announced its customer-focused strategy to enhance IP outcomes from improved data-enabled IP decision-making and improved IP productivity across the industry. After the acquisition of ipan/Delegate Group, CPA global operates in two core business divisions namely Software and Tech-Enabled Services.

Request a free sample copy or view report summary: Intellectual Property Management Software Market Report

Intellectual Property Management Software Market Report Highlights

• The service component segment is expected to dominate the market owing to the increasing demand for post-sale services for software across the globe. The segment is expected to reach USD 237.8 million by 2028
• The cloud deployment segment is anticipated to expand at the highest CAGR of 16.3% over the forecast period
• The commercial end-user segment is expected to dominate the market over the forecast period. It is anticipated to reach USD 255.2 million by 2028
• The patent management segment is anticipated to witness the fastest CAGR of 16.1% over the forecast period. The growth can be attributed to increasing patent registrations and applications globally
• North America is projected to account for the largest market share over the forecast period. The regional market is anticipated to reach USD 163.9 million by 2028. The rapid adoption of technological innovations and the presence of various prominent players in the region are some of the major growth drivers for the market in this region
• Prominent industry participants include Anaqua Inc.; Innovation Asset Group, Inc.; Gemalto NV; CPA Global; and Questel

Access Press Release@ https://www.grandviewresearch.com/press-release/global-intellectual-property-management-software-market

Intellectual Property Management Software Market Segmentation

Grand View Research has segmented the global intellectual property management software market based on component, deployment type, end-user, application, and region:

Intellectual Property Management Software Component Outlook (Revenue, USD Million, 2018 - 2028)

• Service
• Software

Intellectual Property Management Software Deployment Type Outlook (Revenue, USD Million, 2018 - 2028)

• On-premise
• Cloud

Intellectual Property Management Software End-user Outlook (Revenue, USD Million, 2018 - 2028)

• Individual
• Commercial

Intellectual Property Management Software Commercial Outlook (Revenue, USD Million, 2018 - 2028)

• BFSI
• IT & Telecom
• Automotive
• Technology
• Others

Intellectual Property Management Software Application Outlook (Revenue, USD Million, 2018 - 2028)

• Patent Management
• Trade Management
• Licensing

Intellectual Property Management Software Regional Outlook (Revenue, USD Million, 2018 - 2028)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
• Asia Pacific
  • China
  • India
  • Japan
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa

List of Key Players of Intellectual Property Management Software Market

• Anaqua Inc.
• Questel
• Gemalto NV
• CPA Global
• Innovation Asset Group Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.